Emerging Issues in Oncology-Updates from MASCC Recorded Activity Webinar
Originally Presented Thursday, August 24, 2017
- Interpret results from recent clinical studies presented at the MASCC 2017 meeting.
- Compare and contrast the recent results presented at MASCC 2017 meeting with those already published.
- Examine efficacy and safety of novel investigational agents in supportive care.
Statement of Need/Activity Purpose:
This session TBD
Speaker: J. Andrew Skirvin, PharmD BCOP
Dr. Skirvin is an inpatient hematology/oncology pharmacist practicing in the area of adult solid tumors and hematologic malignancies at Dana Farber Cancer Institute & Brigham & Women's Hospital in Boston. Dr. Skirvin is an Associate Clinical Professor at Northeastern University. Dr. Skirvin received his BS in pharmacy from Oregon State University in 1992 and his Doctor of Pharmacy from the University of Texas at Austin in 1995. Dr. Skirvin completed a oncology pharmacy residency at the Audie Murphy Veterans Hospital in San Antonio in 1996. Dr. Skirvin's areas of interest include supportive care for cancer patients, oncologic emergencies, pain & symptom management, immune therapies, AML, NHL, lung cancer, head & neck cancers, and GI cancers.
Disclosure: Grifols–SP(NCEG); Grifols–A(CEG)
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-17-052-L01-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Tests must be completed by December 31, 2017.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Individual webinar pricing: $40 (member) / $70 (non-member)